Medication Use Linked to Weight Gain in Postmenopausal Women
Use of antidepressants, beta-blockers, insulin linked to increase in BMI, waist circumference.
Obstetrics and Gynecology
Pap/HPV Cotesting Better for Cervical Cancer Screening in Over 30s
Nondetection rate is 13.1% for cotesting, higher when testing is done >12 months prediagnosis.
Higher Rates of Pain, Bleeding Found With Essure Birth Control Device
In 2018, Essure maker Bayer pulled the device from the US market due to concerns about side effects.
Sustained Clinical Benefits Observed With Linzagolix in Uterine Fibroid Trials
Positive topline data were announced from two phase 3 studies evaluating the efficacy and safety of linzagolix (Yselty®; ObsEva) for the treatment of heavy menstrual bleeding due to uterine fibroids.
Clinically Meaningful Pain Reduction Observed With Relugolix in Endometriosis Trial
Positive topline results were announced from the phase 3 SPIRIT 1 study investigating relugolix (Myovant Sciences), in combination with estradiol and norethindrone acetate, in women with pain associated with endometriosis.
Contraceptives Beneficial for Premature Ovarian Insufficiency
Combined oral contraceptives linked to improvement in bone mass, similar to that with high-dose HT.
Oral Contraceptive With Novel Estrogen Under FDA Review
The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).
Newborn Respiratory Distress Up With Maternal Antidepressant Use
Moderate, high sustained prenatal antidepressant use associated with increased risk for preterm birth.
Benzodiazepine Use Linked to Risk for Ectopic Pregnancy
Excess of 80 ectopic pregnancies per 10,000 pregnancies found in women with benzodiazepine prescription.
Oriahnn Approved for Heavy Menstrual Bleeding Due to Uterine Fibroids
The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
